studies

renal cell cancer (RCC), everolimus vs. ..., meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 025, 2015 (REV) 1.37 [1.07; 1.75] 1.37[1.07; 1.75]CheckMate 025, 2015 (REV)10%821NAnot evaluable progression or deaths (PFS)detailed resultsCheckMate 025, 2015 (REV) 1.14 [0.97; 1.33] 1.14[0.97; 1.33]CheckMate 025, 2015 (REV)10%821NAnot evaluable objective responses (ORR)detailed resultsCheckMate 025, 2015 (REV) 0.17 [0.10; 0.27] 0.17[0.10; 0.27]CheckMate 025, 2015 (REV)10%821NAnot evaluable TRAE (any grade)detailed resultsCheckMate 025, 2015 (REV) 1.98 [1.35; 2.91] 1.98[1.35; 2.91]CheckMate 025, 2015 (REV)10%803NAnot evaluable TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 2.50 [1.81; 3.45] 2.50[1.81; 3.45]CheckMate 025, 2015 (REV)10%803NAnot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 025, 2015 (REV) 4.11 [0.18; 91.35] 4.11[0.18; 91.35]CheckMate 025, 2015 (REV)10%803NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 025, 2015 (REV) 1.82 [1.14; 2.91] 1.82[1.14; 2.91]CheckMate 025, 2015 (REV)10%803NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 4.83 [2.10; 11.10] 4.83[2.10; 11.10]CheckMate 025, 2015 (REV)10%803NAnot evaluable Cough TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.02 [0.02; 51.67] 1.02[0.02; 51.67]CheckMate 025, 2015 (REV)10%803NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 2.06 [0.37; 11.29] 2.06[0.37; 11.29]CheckMate 025, 2015 (REV)10%803NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.02 [0.29; 3.56] 1.02[0.29; 3.56]CheckMate 025, 2015 (REV)10%803NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.02 [0.02; 51.67] 1.02[0.02; 51.67]CheckMate 025, 2015 (REV)10%803NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 0.68 [0.11; 4.09] 0.68[0.11; 4.09]CheckMate 025, 2015 (REV)10%803NAnot evaluable Epistaxis TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.02 [0.02; 51.67] 1.02[0.02; 51.67]CheckMate 025, 2015 (REV)10%803NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.13 [0.47; 2.69] 1.13[0.47; 2.69]CheckMate 025, 2015 (REV)10%803NAnot evaluable Mucosal inflammation TRAE (grade 3-4)detailed resultsOut of scaleCheckMate 025, 2015 (REV) 25.28 [1.49; 429.40] 25.28[1.49; 429.40]CheckMate 025, 2015 (REV)10%803NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 3.08 [0.32; 29.77] 3.08[0.32; 29.77]CheckMate 025, 2015 (REV)10%803NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 4.11 [0.18; 91.35] 4.11[0.18; 91.35]CheckMate 025, 2015 (REV)10%803NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.90 [0.70; 5.19] 1.90[0.70; 5.19]CheckMate 025, 2015 (REV)10%803NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.02 [0.02; 51.67] 1.02[0.02; 51.67]CheckMate 025, 2015 (REV)10%803NAnot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 025, 2015 (REV) 1.54 [0.26; 9.25] 1.54[0.26; 9.25]CheckMate 025, 2015 (REV)10%803NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsOut of scaleCheckMate 025, 2015 (REV) 36.28 [2.17; 606.14] 36.28[2.17; 606.14]CheckMate 025, 2015 (REV)10%803NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-07-02 16:58 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 10,93,79,178,152,80 - treatments: 507,1040

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons